Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID by Iguchi, A et al.
ORIGINAL ARTICLE
Successful reduced-intensity SCT from unrelated cord blood in three
patients with X-linked SCID
A Iguchi
1, N Kawamura
1, R Kobayashi
2, S-I Takezaki
1, Y Ohkura
1, J Inamoto
1, J Ohshima
1,
M Ichikawa
1, T Sato
1, M Kaneda
1, Y Cho
1, M Yamada
1, I Kobayashi
1 and T Ariga
1
1Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan and
2Department of Pediatrics,
Sapporo Hokuyu Hospital, Sapporo, Japan
We describe three males with X-linked SCID (X-SCID) who
were successfully treated by reduced-intensity SCT from
unrelated cord blood (CB). Mean age at transplant was 5.7
months (range, 3–9 months). Pre-transplant conditioning for
all patients consisted of ﬂudarabine (FLU) (30mg/m
2 per
day) from day  7t od a y 2 (total dose 180mg/m
2)a n dB U
4mg/kg per day from day  3t od a y 2 (total dose 8mg/
kg). All CB units were serologically matched at HLA-A, B
and DR loci. Although two patients had suffered from fungal
or bacterial pneumonia before transplantation, there were no
other infectious complications during transplantation. All
patients engrafted and achieved 100% donor chimerism. We
also conﬁrmed full donor chimerism of both T and B cells.
Only one patient developed acute GVHD grade III, which
was resolved by increasing the dose of oral corticosteroid.
None of the patients has developed chronic GVHD during
follow up for 21–77 months. None of the patient received i.v.
Ig replacement post transplant, or showed delay in
psychomotor development. Reduced-intensity conditioning
consisting of FLU and BU and transplantation from
unrelated CB was an effective and safe treatment for these
patients with X-SCID.
Bone Marrow Transplantation (2011) 46, 1526–1531;
doi:10.1038/bmt.2010.338; published online 24 January 2011
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Introduction
SCID is the most severe form of primary immunodeﬁ-
ciency. About half of all cases are X-linked SCID (X-SCID;
T-BþNK-SCID), caused by deﬁcits of cytokine receptor
common gamma chain.
1 Haematopoietic SCT is the only
curative treatment for these high-risk patients.
2,3 In the
early series, HLA-identical sibling BMT led to complete
immunological reconstitution with no conditioning regi-
men.
4,5 Thereafter, transplants from closely matched
unrelated volunteer donor (MUD) have been performed
with better outcomes in terms of both survival and
immunological reconstitution than following those using
haploidentical donors; the majority of patients with
myeloablative conditioning no longer required i.v. Ig
replacement after MUD transplantation.
2,5,6 However,
MUD transplantation can require a lengthy search for a
suitable donor, often over 3 months, and is associated with
both high frequency and intensity of GVHD. Moreover,
immunological reconstitution is often incomplete especially
with X-SCID after MUD transplant with no conditioning.
4
Most of these problems are resolvable by transplanting
with umbilical cord blood (CB) already typed with a known
number of CD34 cells supplied from CB bank, when a
lower incidence of GVHD is seen.
7–9 Following the ﬁrst
report of CB SCT (CBT) for primary immunodeﬁciency
patients using their sibling donors,
10 successful unrelated
CBTs have been described.
11–16 Because the OS rates are
over 70%, CB could be a promising source of stem cells
when an HLA-identical sibling donor is not available.
X-SCID is fatal and requires SCT in the ﬁrst year of life
despite possible late complications such as mental and
physical retardation after myeloablative transplantation
received in infancy.
17–19 On the other hand, most have
already suffered from bacterial and/or fungal infection at
diagnosis of X-SCID. Recently developed reduced-intensity
conditioning (RIC) regimens have been used in unrelated
SCT for primary immunodeﬁciency patients, because of
their intense immune suppressive qualities and reduced
myelotoxicity.
20 Thus, reduced-intensity SCT (RIST) from
CB could be a choice for patients with X-SCID but is not
fully established to date. We report our single centre
experience of successful allogeneic RIST from unrelated CB
for treatment of X-SCID.
Patients and methods
Patients
Three patients with X-SCID received unrelated CBT
because they had no HLA-matched sibling donors. As
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www.nature.com/bmtshown in Table 1, mutations in the common gamma chain
gene were detected in all patients. Patients 1 and 2 had
suffered from pneumonia caused by aspergillus and
bacteria, respectively, at the diagnosis of X-SCID. Patient
3 was diagnosed as having X-SCID at birth because his
brother had the same disease (Table 1).
Conditioning regimen and GVHD prophylaxis
Pre-transplant conditioning for all patients consisted of
ﬂudarabine (FLU) (30mg/m
2 per day) from day  7 to day
 2 (total dose 180mg/m
2) and BU 4mg/kg per day (oral in
patient 1 and 2; i.v. in patient 3) from day  3 to day  2
(total dose 8mg/kg). Neither ATG nor Campath was
included in the conditioning regimen.
Prophylaxis for aGVHD included cyclosporine A (3mg/
kg) from day  1 to day þ180, and methylprednisolone
0.5mg/kg per day (dayþ7t oþ13), 1mg/kg per day
(dayþ14 to þ28), 0.5mg/kg per day (dayþ29 to þ42),
0.3mg/kg per day (dayþ43 to þ56) and 0.2mg/kg per day
(dayþ57 to þ72). Cyclosporine A was discontinued by
dayþ180, after conﬁrming the absence of clinical GVHD.
Graft characteristics
As shown in Table 1, all CBs were collected from female
donors. All of these CB units were serologically well
matched at 6/6 (A, B, DR) HLA loci. Infused nucleated cell
doses were 11–20 10
7/kg (mean, 15 10
7/kg), which
contained CD34þ stem cells, ranging from 3.2 to
6.7 10
5/kg (mean, 5.1 10
5/kg).
Supportive care
Supportive care for transplantation in our institution has
been previously described.
21 Brieﬂy, all patients received
a continuous infusion of low molecular weight heparin,
100 unit/kg per day, as prophylaxis against hepatic veno-
occlusive disease (VOD), from day  7 to day þ30. Oral
polymixin B and amphotericin B, inhaled vancomycin,
tobramycin and amphtericin B were given as antibacterial
and antifungal prophylaxis. Antiviral prophylaxis consisted
of oral acyclovir (600mg/m
2 per day) from day  7 to day
þ35 and weekly i.v. g-globulin (200mg/kg per 2 weeks)
from day  6 to day þ90. G-CSF was given i.v. at 5mg/kg
from day þ5 until the ANC reached 500/mL or more for
3 consecutive days. Oral mucositis was treated with i.v.
pentazocine and parental nutrition.
aGVHD was diagnosed and graded according to the
Seattle criteria,
22 and treated with prednisolone. CMV
infection was diagnosed on the basis of CMV antigenemia,
and treated with ganciclovir in combination with anti-
CMV high titer g-globulin.
Chimerism studies
Hematological recovery was deﬁned as achievement of both
an ANC4500/mL for 3 consecutive days and a platelet
count 450 10
9/L for 7 consecutive days without the need
for transfusion. Chimerism was tested by FISH of
peripheral mononuclear cells using X and Y chromosome
probes. Chimerism of T or B cell lineage was assessed by
ﬂow cytometry using intracytoplasmic staining of common
gamma chain together with ﬂuorescein-labelled antibodies
against CD3 and CD19.
Table 1 Patient characteristics
Patient 1 2 3
Age at diagnosis (months) 8 4 0
Age at CBT (months) 9 5 3
Mutations in common gamma chain 682T4G in exon 5 9_10insA in exon 1 216G4A in exon 2
HLA identity 6/6 6/6 6/6
Nucleated cell dose ( 10
7/kg) 11.2 20.4 15.6
CD34+ cell dose ( 10
5/kg) 6.7 5.3 3.2
Cytomegarovirus serology Positive Positive Positive
Haematological recovery
Neutrophil4500/mL day+19 day+22 Day+27
Platelet450 10
9/L day+28 day+43 Day+31
Complications at CBT aspergillus pneumonia bacterial pneumonia None
Additional infections during CBT None None None
GVHD
Acute(grade) 0 III 0
Chronic — — —
Chimerism (donor%) 100 100 100
B-cell engrafted(donor % (day)) 100 (day+120) 100 (day+89) 100 (day+83)
i.v.Ig replace at present None None None
Performance Status (ECOG, Oken MM et al
35) PS-0 PS-0 PS-0
Outcome Alive +77mo Alive +69mo Alive +21 mo
Height  0.53 s.d.  0.49 s.d.  2.4 s.d.
Body mass index 15.0 16.1 15.6
Mental status Normal Normal Normal
Abbreviations: CBT¼cord blood transplantation; ECOG¼Eastern Cooperative Oncology Group.
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Immunological reconstitution status after transplantation
was monitored by serum immunoglobulin levels (IgG, IgA
and IgM) and ﬂow cytometry analyses of peripheral
mononuclear cells for CD3, CD4, CD8, CD16, CD19 and
CD56.
Results
Engraftment and chimerism
As shown in Figures 1a–c, all patients achieved engraft-
ment of ANC4500/mL at a mean of 22 days (range, 19–27
days). Mean time to platelet engraftment (platelets
450 10
9/L) was 34 days (range, 28–43 days). Donor
chimerism (100%) was demonstrated by FISH with X and
Y chromosome probes at 1-year post transplantation. We
also conﬁrmed full donor chimerism of both T and B cells.
Chimerism has been stable to date with a mean follow-up
of 53 months (range, 21–77 months). Frequencies of
transfusion were similar to the other patients with non-
malignant conditions, such as congenital metabolic dis-
orders, receiving RIST in our institute.
Regimen related toxicity
Patient 1 received anti-fungal treatment with i.v. micafun-
gin 3mg/kg before conditioning until dayþ90 for pre-
existing lung aspergillosis, which showed no exacerbation
during CBT. Clinical and radiological improvement were
achieved after CB engraftment. Patient 2 was already
suffering from bacterial pneumonia on admission; he
received appropriate antibiotic treatment and recovered
at the beginning of conditioning. He had no additional
severe infectious complications up to engraftment. Patient 3
received CBT at 3 months of age with no previous
infections. He also had no severe infectious complications
up to engraftment. Although mild mucositis and increase of
serum transaminase occurred, none of the patients experi-
enced complicated severe regimen related toxicities such as
VOD.
GVHD disease
Only patient 2 developed acute GVHD grade III, consisting
of mild skin rash and diarrhea that resolved by increasing
the oral corticosteroid dose. None of the patients have
developed chronic GVHD or associated complications
during follow-up.
Immunological reconstitution
PBL sub-populations gradually reconstituted in all patients
after UCB transplantations. As shown in the ﬁgures,
peripheral blood CD3-, CD19-, CD56-positive cells gradu-
ally increased up to almost normal age-related levels by
1-year post transplantation. We conﬁrmed common
gamma chain expression in all of these lymphocyte sub-
populations. None of the patient had received further i.v.
Ig replacement by 5–6 months after transplantation.
Moreover, in all the patients, speciﬁc antibodies were
produced against inﬂuenza, pertussis and measles following
vaccination.
Growth and psychomotor development
As shown in Table 1, all three patients have shown normal
psychomotor development and performance status to date.
Only patient 3 had short stature of  2.4 s.d. at 21 months
follow-up at post transplant, although the other two
patients had normal growth development.
Discussion
We describe three patients with X-SCID successfully
treated by CBT with a RIC regimen using FLU/BU. Both
FLU/melphalan (LPAM) and FLU/BU regimens with or
without modiﬁcations such as additional serotherapy are
widely used for RIC regimen.
23,24 Although the FLU/
LPAM regimen results in satisfactory engraftment,
20
LPAM is toxic to both primitive and committed stem cells
resulting in early onset and prolonged duration of
neutropenia.
25 In addition, LPAM-containing conditioning
has been identiﬁed as a risk factor for VOD,
26 possibly
because LPAM induces more severe mucosal injury in the
oral cavity and gastrointestinal tract compared with other
agents.
27–29 On the other hand, BU is preferentially toxic to
committed stem cells.
25 Although conditioning regimens
including standard-dose BU are associated with a high rate
of treatment-related complications due to organ toxicity,
reduced-dose BU in combination with FLU is less
myelosuppressive and toxic than FLU/LPAM or the
standard-dose of BU regimen.
30 Our patients achieved full
donor T- and B-cell chimerism and clinical cure with
minimum complications related to myelotoxicity. To date,
none of our patients has shown mental or growth delay
with the exception of patient 3, who had short stature of
 2.4 s.d. at 21 months after CBT. Growth and endocrine
function are commonly affected by standard myeloablative
conditioning but this has not been reported with BU-based
RIC for SCT during infancy and childhood.
31 Patient 3
possibly has growth retardation following the BU-based
RIC regimen because he underwent SCT at 3 months old.
Further studies are necessary to determine the appropriate
time for SCT to prevent late complications such as growth
retardation.
Although CBT is more tolerant to HLA disparity, HLA
incompatibility increases the incidence and intensity of
GVHD and transplantation-related mortality.
16,32 The low
incidence of severe GVHD in our series of patients possibly
reﬂects the good match of the CB units. As unrelated CB is
immediately available from CB banks, it is advantageous
for patients with X-SCID who need urgent transplantation.
Pre-existing infections are the principal risk factors for a
poor outcome after SCT. Patients 1 and 2 overcame pre-
existing fungal and bacterial pneumonia, respectively, and
recovered after transplantation. This suggests that, in
addition to the appropriate antimicrobial therapy, early
immunological reconstitution with minimum immune
suppression after SCT using a RIC regimen contributes
to the freedom from infection. Detection of fungal Ags or
viral nucleotides by PCR-based techniques is critical for the
early diagnosis and appropriate treatment of infections. On
the other hand, early diagnosis of X-SCID before any
infectious episodes, as shown in patient 3, is necessary for
RIST from CB in patients with X-SCID
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Figure 1 Clinical course of the three patients with X-SCID receiving RIST from CB. a, Patient 1; b, Patient 2; c, Patient 3; ’, WBC; &, Neutrophils
(Neut); n, Reticulocyte (Ret); B, Platelet (Plt); E, CD3; m, CD19;  , CD56; respectively. Note that all patients have engrafted and reached 4500/mL
neutrophils with dayþ19, þ22, þ27, respectively (mean dayþ22). Platelet engraftment (platelets 450 10
9/L) was dayþ28, þ43, þ31, respectively
(mean dayþ34).
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developed neonatal mass-screening by quantitative assay
for T-cell receptor excision circles might be useful for early
diagnosis of patients with a wide variety of SCID
genotypes.
33,34
In conclusion, CBT is a suitable alternative to BMT in X-
SCID patients requiring SCT who have no matched sibling
donors. RIC consisting of FLU and BU is an effective and
safe treatment for such cases. Further studies are necessary
to determine the appropriate time for SCT to minimize late
complications such as growth retardation.
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